Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.03 (-5.40%)
Close on Nov 16, 2026Market cap $124.31MP/E –Yield –
Akebia Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Akebia Therapeutics's total debt was $49.56M at Jun 30, 2026. For fiscal 2025 it was $48.25M, up 24.7% from the year before. The highest annual figure on record is $97.54M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.25M | +24.7% |
| FY2024 | Dec 31, 2024 | $38.69M | +11.6% |
| FY2023 | Dec 31, 2023 | $34.68M | -47.5% |
| FY2022 | Dec 31, 2022 | $66.08M | -32.3% |
| FY2021 | Dec 31, 2021 | $97.54M | +1.2% |
| FY2020 | Dec 31, 2020 | $96.38M | +27.1% |
| FY2019 | Dec 31, 2019 | $75.81M | +405.4% |
| FY2018 | Dec 31, 2018 | $15.00M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $49.56M | +5.3% |
| Q1 FY2026 | Mar 31, 2026 | $48.89M | +5.1% |
| Q4 FY2025 | Dec 31, 2025 | $48.25M | +24.7% |
| Q3 FY2025 | Sep 30, 2025 | $47.64M | +24.2% |
| Q2 FY2025 | Jun 30, 2025 | $47.06M | +23.7% |
| Q1 FY2025 | Mar 31, 2025 | $46.51M | +54.3% |
| Q4 FY2024 | Dec 31, 2024 | $38.69M | +11.6% |
| Q3 FY2024 | Sep 30, 2024 | $38.36M | -10.0% |
| Q2 FY2024 | Jun 30, 2024 | $38.03M | -10.5% |
| Q1 FY2024 | Mar 31, 2024 | $30.15M | -40.1% |
| Q4 FY2023 | Dec 31, 2023 | $34.68M | -47.5% |
| Q3 FY2023 | Sep 30, 2023 | $42.61M | -35.4% |
| Q2 FY2023 | Jun 30, 2023 | $42.49M | -56.7% |
| Q1 FY2023 | Mar 31, 2023 | $50.30M | -48.6% |
| Q4 FY2022 | Dec 31, 2022 | $66.08M | -32.3% |
| Q3 FY2022 | Sep 30, 2022 | $65.95M | -32.2% |
| Q2 FY2022 | Jun 30, 2022 | $98.16M | +1.3% |
| Q1 FY2022 | Mar 31, 2022 | $97.85M | +1.3% |
| Q4 FY2021 | Dec 31, 2021 | $97.54M | +1.2% |
| Q3 FY2021 | Sep 30, 2021 | $97.23M | +26.9% |
| Q2 FY2021 | Jun 30, 2021 | $96.92M | +27.0% |
| Q1 FY2021 | Mar 31, 2021 | $96.61M | +27.0% |
| Q4 FY2020 | Dec 31, 2020 | $96.38M | +27.1% |
| Q3 FY2020 | Sep 30, 2020 | $76.61M | +410.7% |
| Q2 FY2020 | Jun 30, 2020 | $76.34M | – |
| Q1 FY2020 | Mar 31, 2020 | $76.07M | – |
| Q4 FY2019 | Dec 31, 2019 | $75.81M | – |
| Q4 FY2018 | Dec 31, 2018 | $15.00M | – |
See a number that looks wrong?